Sipavibart is an experimental medication under investigation for the prevention of COVID‑19 in people who are immunocompromised.^[1] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.^[1][2]

In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kavigale, intended for the prevention of COVID‑19 in immunocompromised people aged twelve years of age and older.^[1] Kavigale was reviewed under the EMA's accelerated assessment program.^[1] The applicant for this medicinal product is AstraZeneca AB.^[1]

Sipavibart is the international nonproprietary name.^[3]

• Loubet P, Gaborit B, Salpin M, Gardeney H, Benotmane I, Systchenko T (December 2024). "Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France". Human Vaccines & Immunotherapeutics. 20 (1): 2387221. doi:10.1080/21645515.2024.2387221. PMC 11328879. PMID 39143811.
• Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, et al. (2024). "Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies". Pathogens & Immunity. 10 (1): 1–11. doi:10.20411/pai.v10i1.752. PMC 11464000. PMID 39391808.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e